DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy (SMA) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering ...
Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled ...
Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision ...
DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy, Drug), By ...
Muscle atrophy is a primary characteristic of both sarcopenia and cachexia, significantly impacting physical function and quality of life. This figure illustrates the multifaceted causes of muscle ...
Please provide your email address to receive an email when new articles are posted on . Dec. 5 is World Geographic Atrophy Day, a new initiative that seeks to empower individuals with this advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results